Paradigm Biocapital Advisors
Latest statistics and disclosures from Paradigm Biocapital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are NUVL, RVMD, ACLX, GMAB, TARS, and represent 47.45% of Paradigm Biocapital Advisors's stock portfolio.
- Added to shares of these 10 stocks: GMAB (+$99M), ACLX (+$70M), XBI (+$61M), ORKA (+$52M), LXEO (+$47M), SRRK (+$46M), RVMD (+$34M), TERN (+$33M), EYPT (+$31M), VOR (+$23M).
- Started 8 new stock positions in ASMB, ORIC, LXEO, TERN, VOR, ORKA, IVA, KLRS.
- Reduced shares in these 10 stocks: MRUS (-$440M), AGIO (-$115M), JANX (-$71M), , LENZ (-$50M), PHVS (-$46M), COGT (-$45M), CDTX (-$45M), VRDN (-$36M), APGE (-$30M).
- Sold out of its positions in AGIO, AMLX, COGT, IRON, DYN, JANX, LENZ, GPCR, TNGX, ALKS. MRUS, PHVS.
- Paradigm Biocapital Advisors was a net seller of stock by $-467M.
- Paradigm Biocapital Advisors has $3.9B in assets under management (AUM), dropping by 11.42%.
- Central Index Key (CIK): 0001855655
Tip: Access up to 7 years of quarterly data
Positions held by Paradigm Biocapital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Paradigm Biocapital Advisors
Paradigm Biocapital Advisors holds 30 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Nuvalent Inc-a (NUVL) | 13.5 | $530M | 5.3M | 100.59 |
|
|
| Revolution Medicines (RVMD) | 13.5 | $529M | +6% | 6.6M | 79.65 |
|
| Arcellx Common Stock (ACLX) | 9.5 | $373M | +23% | 5.7M | 65.20 |
|
| Genmab A/s Sponsored Ads (GMAB) | 5.5 | $217M | +84% | 7.0M | 30.80 |
|
| Tarsus Pharmaceuticals (TARS) | 5.4 | $210M | -3% | 2.6M | 81.88 |
|
| Abivax Sa Sponsored Ads (ABVX) | 4.9 | $191M | -9% | 1.4M | 134.85 |
|
| Olema Pharmaceuticals (OLMA) | 4.8 | $189M | +11% | 7.5M | 25.00 |
|
| Vaxcyte (PCVX) | 4.8 | $188M | +7% | 4.1M | 46.14 |
|
| Spdr Series Trust State Street Spd Put Option (XBI) | 4.7 | $183M | +50% | 1.5M | 121.93 |
|
| Cidara Therapeutics Com New (CDTX) | 4.3 | $168M | -20% | 760k | 220.89 |
|
| Edgewise Therapeutics (EWTX) | 4.1 | $162M | +6% | 6.5M | 24.82 |
|
| Scholar Rock Hldg Corp (SRRK) | 3.4 | $135M | +52% | 3.1M | 44.05 |
|
| Urogen Pharma (URGN) | 2.7 | $105M | +6% | 4.5M | 23.42 |
|
| Crinetics Pharmaceuticals In (CRNX) | 2.6 | $103M | -13% | 2.2M | 46.55 |
|
| Apogee Therapeutics (APGE) | 2.2 | $85M | -26% | 1.1M | 75.48 |
|
| Eyepoint Com New (EYPT) | 1.7 | $67M | +84% | 3.7M | 18.27 |
|
| Erasca (ERAS) | 1.3 | $53M | +4% | 14M | 3.72 |
|
| Bridgebio Pharma (BBIO) | 1.3 | $52M | 684k | 76.49 |
|
|
| Oruka Therapeutics (ORKA) | 1.3 | $52M | NEW | 1.7M | 30.31 |
|
| Spyre Therapeutics Com New (SYRE) | 1.2 | $48M | 1.5M | 32.76 |
|
|
| Lexeo Therapeutics (LXEO) | 1.2 | $47M | NEW | 4.8M | 9.93 |
|
| Miragen Therapeutics (VRDN) | 1.1 | $45M | -44% | 1.4M | 31.12 |
|
| Ocular Therapeutix (OCUL) | 0.9 | $36M | -16% | 2.9M | 12.14 |
|
| Terns Pharmaceuticals (TERN) | 0.8 | $33M | NEW | 810k | 40.40 |
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 0.7 | $28M | +21% | 2.3M | 12.52 |
|
| Vor Biopharma Com New (VOR) | 0.6 | $23M | NEW | 1.8M | 13.08 |
|
| Assembly Biosciences Com New (ASMB) | 0.6 | $23M | NEW | 665k | 34.01 |
|
| Oric Pharmaceuticals (ORIC) | 0.5 | $20M | NEW | 2.4M | 8.18 |
|
| Inventiva Sa Ads (IVA) | 0.5 | $19M | NEW | 4.0M | 4.65 |
|
| Kalaris Therapeutics (KLRS) | 0.2 | $5.9M | NEW | 700k | 8.44 |
|
Past Filings by Paradigm Biocapital Advisors
SEC 13F filings are viewable for Paradigm Biocapital Advisors going back to 2021
- Paradigm Biocapital Advisors 2025 Q4 filed Feb. 17, 2026
- Paradigm Biocapital Advisors 2025 Q3 filed Nov. 14, 2025
- Paradigm Biocapital Advisors 2025 Q2 filed Aug. 14, 2025
- Paradigm Biocapital Advisors 2025 Q1 filed May 15, 2025
- Paradigm Biocapital Advisors 2024 Q4 filed Feb. 14, 2025
- Paradigm Biocapital Advisors 2024 Q3 filed Nov. 14, 2024
- Paradigm Biocapital Advisors 2024 Q2 filed Aug. 14, 2024
- Paradigm Biocapital Advisors 2024 Q1 filed May 15, 2024
- Paradigm Biocapital Advisors 2023 Q4 filed Feb. 14, 2024
- Paradigm Biocapital Advisors 2023 Q3 filed Nov. 14, 2023
- Paradigm Biocapital Advisors 2023 Q2 filed Aug. 14, 2023
- Paradigm Biocapital Advisors 2023 Q1 filed May 15, 2023
- Paradigm Biocapital Advisors 2022 Q4 filed Feb. 14, 2023
- Paradigm Biocapital Advisors 2022 Q3 filed Nov. 14, 2022
- Paradigm Biocapital Advisors 2022 Q2 filed Aug. 15, 2022
- Paradigm Biocapital Advisors 2022 Q1 filed May 16, 2022